WAYNE - Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the Wattson Temporary Pacing Guidewire limited market release has commenced at Columbia University Irving Medical Center.
The first cases were performed by Dr. Tamim Nazif, Director of Clinical Research, Dr. Susheel Kodali, Professor of Medicine and Director of the Structural Heart and Valve Center, and Dr. Isaac George, Surgical Director of the Heart Valve Center.
Featuring a simple design to create procedural efficiencies, the Wattson Temporary Pacing Guidewire offers dual functionality, supporting both valve delivery and ventricular bipolar pacing during structural heart procedures, including transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV). The device offers a procedural alternative designed to avoid potential complications1, steps1, and costs2 associated with traditional right ventricular pacing. From its flexible distal pigtail shape to its multiple electrode, bipolar design, the Wattson Temporary Pacing Guidewire is engineered to help reduce the risk of ventricular perforation while providing confidence in capture during rapid pacing.
'We are thrilled that our team at Columbia University Irving Medical Center was selected for the Wattson Temporary Pacing Guidewire limited market release and are proud to have completed the first TAVR procedures with this important new device,' said Dr. Tamim Nazif, Director of Clinical Research for Columbia Interventional Cardiovascular Care, Director of the Interventional Cardiology Fellowship Program, and assistant professor in medicine at Columbia University Irving Medical Center. 'The Wattson Temporary Pacing Guidewire facilitated minimalist TAVR procedures with safe and reliable LV pacing throughout our first two days of cases, and we are eager to continue to use it moving forward.'
Teleflex received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Wattson Temporary Pacing Guidewire in May of 2023.
'Providing interventionalists with a new tool specifically engineered to address unmet clinical needs frequently encountered during structural heart procedures is a significant milestone for Teleflex,' said Roger Graham, President and General Manager of the Teleflex Interventional business unit. 'The Wattson Temporary Pacing Guidewire reflects our steadfast focus on filling gaps in existing technologies as well as our commitment to providing more options that further simplify minimalist TAVR and other structural procedures.'
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow, Barrigel, Deknatel, QuikClot, LMA, Pilling, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Contact:
Lawrence Keusch
Email: investor.relations@teleflex.com
Tel: 610.948.2836
TELEFLEX INCORPORATED 
